Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

CARB-X awards funding to German institutions

Dec. 3, 2020

Tc24-C4.10E shows promise for the treatment of Chagas disease

Dec. 3, 2020

Appili initiates new phase III trial of Avigan for treatment of COVID-19

Dec. 3, 2020

Environmental support helps blood stem cells cope

Dec. 3, 2020

Cel-Sci reports preclinical data on LEAPS COV-19 peptides

Dec. 3, 2020

U.K. approval for Pfizer and BioNTech's COVID-19 mRNA vaccine BNT-162b2

Dec. 2, 2020

FDA clears IND for phase I study of DHOHD inhibitor RP-7214 for COVID-19

Dec. 2, 2020

DMC completes positive safety review of CYNKCOVID study

Dec. 2, 2020

Investigator-initiated trial to study Carragelose nasal spray for COVID-19 prophylaxis

Dec. 2, 2020

Edesa initiates phase II/III study of EB-05 for hospitalized patients with COVID-19

Dec. 2, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...